Agios Pharmaceuticals | AGIO - Interest Expense On Debt


Agios Pharmaceuticals reported $1.11B in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
Amgen USD 95.64B 94.98B Jun/2026
Arrowhead Research USD 24.56M 716K Jun/2026
Astellas Pharma JPY 3.91B 320M Mar/2025
AstraZeneca USD 340M 144M Jun/2026
Bayer EUR 675M 87M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Daiichi Sankyo JPY 3.57B 1.4B Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 247M 7M Jun/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
Incyte USD 582K 13K Jun/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
Merck USD 525M 46M Jun/2026
Moderna USD 10.96B 527M Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Novartis USD 462M 119M Jun/2026
Novartis USD 281M 8M Sep/2025
Pfizer USD 667M 4M Jun/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025